Inventor · disambiguated record
Oron Yacoby-Zeevi
Also filed as: YACOBY-ZEEVI ORON
23 granted patents·37 pending applications·343 citations·filing 1998–2024
97Inventor score
Files withNEURODERM LTD35INSIGHT STRATEGY & MARKETING7YACOBY-ZEEVI ORON5HADASIT MED RES SERVICE1INSIGHT STRATEGY MARKETING LTD1
Top patents by PatentIndex Score
60 records- 0196US10258585B2DOPA decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2017·Granted Apr 16, 2019·8 cites·18 claims
- 0296US8193243B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameYACOBY-ZEEVI ORON·Filed 2010·Granted Jun 5, 2012·27 cites·8 claims
- 0396US7863336B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameNEURODERM LTD·Filed 2010·Granted Jan 4, 2011·27 cites·11 claims
- 0495US10813902B2DOPA decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2019·Granted Oct 27, 2020·5 cites·24 claims
- 0595US10624839B2Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2018·Granted Apr 21, 2020·6 cites·10 claims
- 0694US9993451B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameNEURODERM LTD·Filed 2015·Granted Jun 12, 2018·9 cites·15 claims
- 0794US9040590B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameNEURODERM LTD·Filed 2014·Granted May 26, 2015·13 cites·17 claims
- 0894US9040578B2Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for sameNEURODERM LTD·Filed 2014·Granted May 26, 2015·15 cites·23 claims
- 0993US9381249B2Compositions comprising apomorphine and organic acids and uses thereofNEURODERM LTD·Filed 2015·Granted Jul 5, 2016·11 cites·21 claims
- 1093US9040589B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameNEURODERM LTD·Filed 2014·Granted May 26, 2015·11 cites·21 claims
- 1193US9040577B2Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for sameNEURODERM LTD·Filed 2014·Granted May 26, 2015·12 cites·21 claims
- 1292US9101663B2Continuous administration of dopa decarboxylase inhibitors and compositions for sameYACOBY-ZEEVI ORON·Filed 2010·Granted Aug 11, 2015·12 cites·9 claims
- 1391US10022320B2Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2015·Granted Jul 17, 2018·8 cites·4 claims
- 1491US9421267B2Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for sameYACOBY-ZEEVI ORON·Filed 2011·Granted Aug 23, 2016·11 cites·23 claims
- 1589US6475763B1Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying sameINSIGHT STRATEGY & MARKETING·Filed 2000·Granted Nov 5, 2002·30 cites·8 claims
- 1689US2025114315A1Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for sameNEURODERM LTD·Filed 2024·Application pending·0 cites
- 1788US9415108B2Compositions for transdermal delivery of active agentsYACOBY-ZEEVI ORON·Filed 2011·Granted Aug 16, 2016·9 cites·18 claims
- 1887US6153187AUse of glycosaminoglycans degrading enzymes for management of airway associated diseasesINSIGHT STRATEGY & MARKETING·Filed 1998·Granted Nov 28, 2000·67 cites·13 claims
- 1986US2025073193A1Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2024·Application pending·0 cites
- 2085US2025177292A1Method for treatment of parkinson's diseaseNEURODERM LTD·Filed 2024·Application pending·0 cites
- 2185US2023321019A1Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2022·Application pending·0 cites
- 2284US6426209B1Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying sameINSIGHT STRATEGY MARKETING LTD·Filed 2000·Granted Jul 30, 2002·12 cites·4 claims
- 2382US10525134B2Compositions comprising apomorphine and organic acids and uses thereofNEURODERM LTD·Filed 2017·Granted Jan 7, 2020·2 cites·16 claims
- 2481US2023047523A1Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2022·Application pending·0 cites
- 2580US6348344B1Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying sameINSIGHT STRATEGY & MARKETING·Filed 1999·Granted Feb 19, 2002·32 cites·95 claims
- 2679US2023240980A1Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2022·Application pending·0 cites
- 2779US2023096364A1Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2022·Application pending·0 cites
- 2877US2023047847A1Method for treatment of parkinson's diseaseNEURODERM LTD·Filed 2022·Application pending·0 cites
- 2974US2021077442A1Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2020·Application pending·0 cites
- 3073US9999674B2Compositions comprising apomorphine and organic acids and uses thereofNEURODERM LTD·Filed 2013·Granted Jun 19, 2018·1 cites·14 claims
- 3172US2020397730A1Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2020·Application pending·0 cites
- 3272US2021000777A1Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2020·Application pending·0 cites
- 3370US6423312B1Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteriaINSIGHT STRATEGY & MARKETING·Filed 1998·Granted Jul 23, 2002·15 cites·1 claims
- 3469US2021093560A1Method for treatment of parkinson's diseaseNEURODERM LTD·Filed 2020·Application pending·0 cites
- 3568US2021038505A1Dopa decarboxylase inhibitor compositionsNEURODERM LTD·Filed 2020·Application pending·0 cites
- 3668US2019125708A1Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2018·Application pending·0 cites
- 3763US12097185B2Compositions comprising ciprofloxacin and celecoxibNEUROSENSE THERAPEUTICS LTD·Filed 2022·Granted Sep 24, 2024·0 cites·20 claims
- 3862US2016022573A1Method for treatment of parkinson's diseaseNEURODERM LTD·Filed 2014·Application pending·0 cites
- 3961US2004146497A1Therapeutic and cosmetic uses of heparanasesFiled 2004·Application pending·0 cites
- 4061US2017157077A1Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for sameNEURODERM LTD·Filed 2016·Application pending·0 cites
- 4160US2013253056A1Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2013·Application pending·0 cites
- 4260US2005260187A1Therapeutic and cosmetic uses of heparanasesHADASIT MED RES SERVICE·Filed 2005·Application pending·0 cites
- 4359US2003068806A1Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying sameFiled 2002·Application pending·0 cites
- 4458US2003161823A1Therapeutic and cosmetic uses of heparanasesFiled 2003·Application pending·0 cites
- 4557US2004213789A1Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodiesFiled 2003·Application pending·0 cites
- 4655US2004170631A1Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodiesFiled 2003·Application pending·0 cites
- 4755US2017196828A1Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for SameNEURODERM LTD·Filed 2016·Application pending·0 cites
- 4855US2004175371A1Introducing a biological material into a patientFiled 2004·Application pending·0 cites
- 4952US2006269552A1Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodiesYACOBY-ZEEVI ORON·Filed 2004·Application pending·0 cites
- 5051US2003031660A1Method of inducing bone formationINSIGHT STRATEGY & MARKETING·Filed 2002·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Oron Yacoby-Zeevi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →